Delivery Order SPE2DB24D2010-SPE2DB25FAACQ
- Not listed
- The Defense Logistics Agency awarded a $2,324.75 firm fixed price delivery order to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) CF pen 40 mg/0.4 mL on November 14, 2025, with completion targeted for November 17, 2025. This is an unset-aside, competitively awarded contract with place of performance in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at...
- The Defense Logistics Agency awarded a delivery order valued at $1,529.47 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) CF Pen 40 mg/0.4 mL pharmaceutical supply. This contract, awarded on July 28, 2025, with an ultimate completion date of July 29, 2025, represents a firm fixed-price delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency awarded a delivery order valued at $3,054.51 to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 40 mg/0.4 mL pharmaceutical supply. This firm fixed-price delivery order, awarded on August 7, 2025, with an ultimate completion date of August 8, 2025, represents a non-set-aside competitive award. The product will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under a larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on July 28, 2025, with a ceiling value of $2,265.90 and an ultimate completion date of July 29, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The place of performance is listed as Conshohocken, Pennsylvania, which is AmerisourceBergen's headquarters location. This delivery order is a child contract issued...
- The Defense Logistics Agency awarded a $3,700.03 firm fixed-price delivery order to AmerisourceBergen Drug Corp on November 6, 2025, for the supply of HUMIRA (adalimumab) CF Pen 40 mg/0.4 mL. The contract, with an ultimate completion date of November 7, 2025, represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. This award involved no set-aside designation and was competitively awarded. AmerisourceBergen, a major...
- The Defense Logistics Agency awarded a delivery order valued at $19,164.60 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) 40 mg/0.4 mL prefilled pens. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 26, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters and primary pharmaceutical distribution...
- The Defense Logistics Agency awarded a $1,510.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mL pharmaceutical supplies on September 3, 2025, with completion targeted for September 4, 2025. This non-competitive delivery order is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $19,774.30 firm fixed price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-competitive delivery order was issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which carries a ceiling value of $999,999,999.00 through December 2026. The performance location is AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $2,152.36 to AmerisourceBergen Drug Corp for the supply of HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL. This competitively awarded, firm fixed-price contract was issued on June 2, 2025, with an ultimate completion date of June 3, 2025. The place of performance is listed as AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a child contract, this delivery order is issued under AmerisourceBergen's broader...
- The Defense Logistics Agency awarded a $3,715.82 delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of HUMIRA (Adalimumab) CF Pen 40 mg/0.4 mL. This competitively awarded, firm fixed-price contract is set to conclude on October 28, 2025, with performance executed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply relationship with the...
- SPE2DB24D2010Indefinite Delivery Contract
- SPE2DB24D2010-SPE2DB25FAACQDelivery Order
The Defense Logistics Agency awarded a $20,755.70 delivery order to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) pen 40 mg/0.4 mL on June 30, 2025, with an ultimate completion date of July 1, 2025. This contract employs firm fixed-price pricing with no set-aside designation, indicating competitive award to this pharmaceutical distributor. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.99 billion vehicle running through December 2026 that serves as a comprehensive global pharmaceutical support program for military healthcare systems. AmerisourceBergen Drug Corp is a major pharmaceutical distributor providing critical medical procurement support to federal defense and healthcare systems, with an extensive portfolio of brand-name and generic medications, vaccines, and medical devices across multiple therapeutic domains. The parent IDC with DLA Troop Support Medical demonstrates the company's capability to meet federal procurement requirements and serve customers including the Defense Health Agency and U.S. Coast Guard. The delivery of HUMIRA, a widely-used immunosuppressant biologic medication, supports pharmaceutical supply requirements within the military medical supply chain and contributes to the comprehensive healthcare support provided to servicemembers and veterans.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $20.8k | 6/30/25 |